# REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

> **NCT01762592** · PHASE3 · WITHDRAWN · sponsor: **Heidelberg Pharma AG**

## Conditions studied

- Renal Cell Carcinoma
- Kidney Cancer

## Interventions

- **DRUG:** Iodine (124I) Girentuximab

## Key facts

- **NCT ID:** NCT01762592
- **Lead sponsor:** Heidelberg Pharma AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-12
- **Primary completion:** 2018-12-01
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** new sponsor
- **Last updated:** 2017-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01762592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01762592, "REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01762592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*